Gamifant
Active Ingredient(s): Emapalumab-lzsgFDA Approved: * November 20, 2018
Pharm Company: * NOVIMMUNE S.A.
Category: Genetic Disorders
Emapalumab, sold under the brand name Gamifant, is an anti-interferon-gamma (IFNγ) antibody medication used for the treatment of hemophagocytic lymphohistiocytosis (HLH),[3][4][5] which has no cure.[6] The most common side effects include infections, hypertension, infusion-related reactions, and pyrexia.[3] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7&a... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.